Background: The aim of this study was to examine the effects of gastric medicines on gastroduodenal injury during antiplatelet therapy after coronary intervention. Methods: A total of 501 patients were enrolled and as dual antiplatelet therapy, aspirin and thienopyridine were administered. Patients were divided into four groups: histamine H2-receptor antagonists (H2RA); proton pump inhibitors (PPI); other gastromucosal protective agents (GMP); or nothing (None), and follow-up lasted 8-20 months. Results: H2RA were prescribed in 212 cases (42%), PPI in 150 (30%), GMP in 56 (11%), and None in 83 (17%). Significant findings by endoscopy were recognized in 18 cases and upper gastrointestinal bleeding requiring hospitalization occurred in 7 patients (1.4%; H2RA in 4, GMP in 2, and None in 1). There were no gastrointestinal injuries in the PPI group. To minimize the effect of selection bias on gastroduodenal lesions, the propensity score analysis for clinical characteristics was used. The results of propensity score matching showed that administration of PPI reduced the incidence of gastrointestinal lesions compared with that of the non-PPI group. Conclusion: Administration of PPI reduced the incidence of gastrointestinal lesions compared with that of the non-PPI group.
Introduction
It is widely accepted that antiplatelet therapy has preventive effects against cardiovascular events in patients with coronary artery disease (CAD) [1] . In cases of deployment of drug-eluting stents, dual antiplatelet therapy is continued at least for about 6 months post-stent in many hospitals [2] . Aspirin, which is a non-steroidal anti-inflammatory drug, and also other antiplatelet agents have been reported to have gastrointestinal toxicity that limits their use [3] . It remains unclear which is an appropriate and effective medicine for inhibiting gastrointestinal injury in patients with CAD after percutaneous coronary intervention (PCI). Thus, the aim of this study was to examine the preventive effects of gastric agents against gastroduodenal injury in patients on antiplatelet therapy.
Methods

Subjects
A total of 501 patients who underwent PCI for diagnosis of stable angina in our institutes during 2007 were enrolled in this analysis (male 341 cases, mean age 71 years) and background characteristics including the prescribed medications in all of these cases were retrospectively ascertained from medical records. As dual antiplatelet therapy, aspirin 100 mg/day and ticlopidine 200 mg/day, or clopidogrel 75 mg/day were administered. The selection of gastric agents was determined by each attending physician. Patients were divided into four groups: histamine H2-receptor antagonists (H2RA); proton pump inhibitors (PPI); other gastromucosal protective agents (GMP); or nothing (None). The study protocol was in agreement with the guidelines of the ethical committee of the institution and written informed consent was obtained from each patient or the family of the subject.
Angioplasty procedure
PCI was performed according to the standard technique, and in one vessel per patient. Conventional treatment was given during angioplasty, including isosorbide dinitrate and heparin. Additional heparin was administered each hour in long procedures. The technical aspects of the procedure, including the choice of stent and balloon, duration of inflation and pressure, were determined by each operator.
Endoscopy
In cases complaining of upper gastrointestinal symptoms, endoscopic examination was performed according to the standard technique. Gastroduodenal injury was defined as obvious findings of ulcer or erosion including bleeding, but excluding esophageal lesions, atrophic gastritis, and malignancies.
Definitions and follow-up
Hypertension was defined as systolic blood pressure >140 mmHg or diastolic pressure >90 mmHg. Diabetic mellitus was defined according to World Health Organization (WHO) criteria. Patients were followed by hospital visits or telephone interview, and if necessary, the examination of gastrointestinal endoscopy was advised.
Statistical analysis
Statistical analysis was performed as follows. All values are expressed as mean ± S.D. Statistical analysis of the differences in clinical characteristics among the four groups was performed using Wilcoxon nonparametric test or chi-square test.
Propensity score analysis
In an additional effort to balance the patient groups, we used propensity score analysis to generate a set of matched cases (patients with PPI administration) and controls (patients without PPI administration), as previously described [4] . The propensity score was calculated for each patient based on a logistic regression analysis of the probability of PPI prescription using clinical characteristics. With these propensity scores, we then used a greedy matching technique to create a 1-to-1 match of cases with controls as described by Parsons [5] . Comparisons between the two matched groups based on clinical characteristics were carried out using chi-square test or unpaired t-test to confirm that the groups had been successfully matched. We calculated the incidences of gastroduodenal ulcer and gastritis/duodenitis confirmed by endoscopy between the two matched groups. A P-value <0.05 was defined as statistical significance.
All analyses were performed using the SAS software package version 9.1 (SAS, Cary, NC, USA). 
Results
The clinical characteristics of each group are shown in Table 1 . Stomach medicines were H2RA in 212 cases (42%), PPI in 150 (30%), GMP in 56 (11%), and None in 83 (17%). There were significant differences in age and prior gastroduodenal lesions among the four groups, and it seemed that the PPI group had higher age and higher incidence of prior gastrointestinal lesions. Antiplatelet therapies at discharge were aspirin alone in 15 patients, aspirin + thienopyridine in 465, and aspirin + other platelets in 21. Follow-up lasted 8-20 months. Gastroduodenal endoscopy was performed in 31 of the 501 cases (6.2%), and the reasons for undergoing endoscopy were upper abdominal symptoms such as epigastric pain, discomfort, early satiety after eating, or bloating, and follow-up study of prior gastrointestinal diseases. As shown in Table 2 , significant findings were recognized in a total of 18 of the 31 cases and details were 10 in H2RA (4.7%), 2 in PPI (1.3%), 3 in GMP (5.4%), and 3 in None group (3.6%), respectively. Although special treatment including hospitalization was needed in seven patients (four in H2RA, two in GMP, and one in None groups), there was no severe gastrointestinal injury in the PPI group (Table 3) . Two cases required blood transfusion in the GMP and None groups. Five of the seven patients experienced gastrointestinal injury within 2 months, and the lesions were detected within a maximum of 6 months in all subjects. In terms of antiplatelet therapy, six patients were taking aspirin and thienopyridine, and one aspirin alone (case no. 7 in Table 3 ). To minimize the effect of selection bias on gastroduodenal lesions, the propensity score matching for clinical characteristics such as age, sex, hypertension, diabetes, prior gastroduodenal lesion, or hemodialysis, was used. In the present study, 143 cases were successfully matched in a 1:1 manner with 143 corresponding controls ( Table 4 ). The results of propensity score matching showed that administration of PPI reduced the incidence of gastrointestinal lesions and hospitalization necessitating special treatment compared with the non-PPI group (Table 4) .
Discussion
In Japan compared with western countries, H2RA are more popular than PPI for cardiologists as prophylactic administration against gastroduodenal mucosal injury during antiplatelet therapy [6] . Gastric damage associated with the use of antiplatelet agents occurred not only in the GMP group but also in the H2RA group, however, not in the PPI group in this study. Thus, as well as previous reports, PPI may be more appropriate and effective than H2RA in healing and preventing ulcers during antiplatelet therapy [7] . As shown in Table 1 , the rate of prior gastroduodenal lesions was highest in the PPI group (15/150, 10%). Although the frequency of H2RA use was the highest among the gastric agents in the present study, the detailed examination of medical records revealed the preferred use of PPI in cases of prior gastroduodenal injury or upper gastrointestinal surgical operation. Despite this difficult situation with high risk of occurrence or recurrence of upper gastrointestinal lesions, there were no serious cases requiring hospitalization in the PPI group. Moreover, to minimize the effect of selection bias on outcomes, we used the technique of propensity score matching for clinical characteristics and excluded distortion of confounding factors. Based on propensity score analysis, PPI treatment reduced significantly the incidence of gastroduodenal damage and hospitalization necessitating special treatment compared with non-PPI treatment. There have been no studies that show a reduction in the risk of upper gastrointestinal injury in stable angina patients with the use of PPI, thus these results may indicate the efficacy of PPI therapy after PCI for protection against gastroduodenal injuries. Yamamoto et al. [8] showed the incidence of gastroduodenal mucosal injury and bleeding in patients on antiplatelet therapy and 75% of all patients (262/350) were on aspirin alone. Moreover, although the report by Chin et al. [9] demonstrated predictive and protective factors associated with upper gastrointestinal bleeding after PCI, most of the patients had acute coronary syndrome, not stable angina. In this study, patients with stable angina were examined as subjects, and the rate of aspirin Although we used the technique of propensity score matching between the PPI and non-PPI groups, there are some limitations to this study, such as retrospective, small number, and bias by attending physician in selection of gastric medication, moreover, upper gastrointestinal endoscopy was not performed in all patients, and the number of cases studied by endoscopy was very small. Furthermore, high-age patients may not complain about upper gastrointestinal symptoms, and there may be a possibility to miss those patients, and we excluded the relationship between antiplatelet therapy and malignancy. However, these results provide useful information regarding gastroduodenal injury in patients with chronic CAD on antiplatelet therapy. Considering the importance of antiplatelet therapy in not only CAD but also atherothrombotic diseases, further prospective study is needed in the future.
Finally, the relation between heart and stomach has been sporadically reported until now; for example, inferior myocardial infarction may be wrongly diagnosed as upper gastrointestinal disease due to the symptoms of vomiting and nausea [10] , and we reported a case of angina-like disease due to cardiac compression by a giant hiatal hernia [11] . In the present study, we suggested the risk of gastroduodenal injury during antiplatelet therapy in patients with CAD. Considering that these findings drew cardiologists' attention to the interaction between heart and stomach in the broad sense, we propose an idea of ''cardio-gastric linkage''.
